Business Wire

easyJet to Unlock Environmental, Operational Benefits as First Airline Partner for Iris Programme From Inmarsat, ESA

21.6.2022 12:00:00 EEST | Business Wire | Press release

Share

easyJet has today been announced as the first airline partner of the ground-breaking Iris programme by Inmarsat and the European Space Agency (ESA), which utilises the latest generation of satellite technology to modernise air traffic management (ATM).

One of Europe's leading airlines will play a central role in the Iris programme, which enables real-time collaboration between pilots, air traffic controllers and airline operation centres using secure, high-bandwidth data links. This minimises delays, saves fuel and reduces environmental impact for airlines, while also improving airspace usage to ease congestion and accommodate future growth.

Powered by Inmarsat’s award-winning SwiftBroadband-Safety (SB-S) connectivity platform, Iris enables new ATM functionalities such as trajectory-based operations that pinpoint aircraft in four dimensions (latitude, longitude, altitude and time), which will allow the airline to avoid holding patterns, calculate the shortest available routes and optimum altitudes, and benefit from continuous climb and descent pathways. The additional datalink capacity provided by SB-S will power a host of powerful onboard digital applications, such as AI flight profile optimisers and real-time weather applications.

With the support of leading Air Navigation Service Providers (ANSPs), easyJet will evaluate Iris’ transformative capabilities on up to 11 Airbus A320neos, set to begin flying from November 2022.

This partnership is the culmination of years of work and over €50 million investment by ESA, Inmarsat and more than 30 partners to develop the Iris programme. It also supports easyJet’s commitment to achieve net-zero carbon emissions by 2050 as part of the UN-backed ‘Race to Zero’ campaign, with an interim target of a 35% carbon emissions intensity improvement by 2035.

Philippe Carette, President of Inmarsat Aviation, said, “The Iris programme from Inmarsat and ESA is a game-changer and we are delighted to have easyJet as our first airline partner. This is not only because of its pioneering commitment to innovation and reducing aviation’s environmental impact, but also because this kick-starts an exciting new era that will help make aviation greener and reduce congestion delays for passengers.”

Hugh McConnellogue, easyJet’s Director of Airport Operations and Navigation, said, “Iris is paving the way for more efficient air traffic management, which is a crucial step forward for the aviation industry. The programme brings multiple benefits, from helping us to achieve our environmental goals by further reducing our carbon emissions, to providing a better experience for our passengers. We’re excited to be leading in this space, setting the standard for the industry and hope to see more airlines follow suit.”

Elodie Viau, Director of Telecommunications and Integrated Applications at ESA, said: “This innovation has been an enormous undertaking by ESA, Inmarsat and more than 30 other companies within the space and aviation industry, so to see it finally ‘take to the skies’ in a live operational environment is very exciting. European airspace is crying out for a solution to its capacity issues, and advanced satellite technology is the only way to set the industry up for a better – and greener – future.”

The easyJet Airbus A320neo aircraft have been linefitted with a Light Cockpit Satcom (LCS) solution powered by terminal manufacturer Cobham, which is integrated fully with the Flight Operations & Maintenance Exchanger (FOMAX) developed by Collins and Airbus.

Iris will enter commercial and operational service fully in Europe next year, supporting the Single European Sky’s ATM Research (SESAR) masterplan. It will be the first communication service to benefit from a Pan-European certification from the European Aviation Safety Agency (EASA).

Earlier this month, Inmarsat and ESA signed a new contract to globalise the programme. Iris Global will focus on the technologies and certification required to share the fuel, CO2 and congestion-saving benefits of Iris with regions beyond Europe. To accelerate further ATM modernisation, it will also adopt System Wide Information Management (SWIM) applications to facilitate greater sharing of information such as airport operational status, weather information, flight data and airspace restrictions status. Research on future capabilities for the integration of uncrewed aviation into European airspace will also be supported.

ENDS

ABOUT INMARSAT

Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.

In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications. The deal is scheduled to close in the second half of 2022.

For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.

ABOUT EASYJET

easyJet is Europe’s leading airline offering a unique and winning combination of the best route network connecting Europe's primary airports, with great value fares and friendly service. easyJet flies on more of Europe’s most popular routes than any other airline and carried more than 96 million passengers in 2019 – more than 16 million travelling for business. The airline has over 300 aircraft on nearly 1000 routes to more than 150 airports across 35 countries. Over 300 million Europeans live within one hour's drive of an easyJet airport.

easyJet aims to be a good corporate citizen, employing people on local contracts in eight countries across Europe in full compliance with national laws and recognising their trade unions. The airline supports several local charities and has a corporate partnership with UNICEF which has raised over £14m for the most vulnerable children since it was established in 2012.

The airline takes sustainability seriously and is committed to reaching net-zero carbon emissions flying by 2050. Together with its partners, including Airbus, Rolls-Royce, Cranfield Aerospace Solutions and Wright Electric, easyJet is working to accelerate the development of zero-emission aircraft technology. In the meantime, the airline is offsetting the carbon emissions from the fuel used for all its flights, at no additional cost to its customers, and only supports projects that are certified by Gold Standard or the Verified Carbon Standard, internationally recognised certification schemes. In addition, easyJet continues to renew its fleet, operate efficiently, and aims to fill most of its seats.

Innovation is in easyJet’s DNA – since launching over 25 years ago, easyJet changed the way people fly to the present day where the airline leads the industry in digital, web, engineering and operational innovations to make travel more easy and affordable for its passengers. The airline was named as Britain’s Most Admired Company of 2020 in the transport sector, retaining the leading position for a second year running. Britain's Most Admired Companies study is the longest-running annual survey of corporate reputation in the UK.

ABOUT ESA

The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. For more information see esa.int.

The Telecommunications and Integrated Applications Directorate (TIA) supports innovation to boost the competitiveness of European industry in the global space market. This involves a wide range of activities, from space-based technology, systems, products for telecommunications development to the down-to-Earth application of space-based services. It also calls for engagement with a wide range of industrial, academic, and institutional partners.

For more information, please visit our website: https://artes.esa.int/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jonathan Sinnatt/Matthew Knowles
Corporate Communications
Tel: +44 (0) 7889 605 272 / +44 (0) 7725 475 507
press@inmarsat.com

Alex Holt
Marketing Business Partner, Inmarsat Aviation
Tel: +44 (0) 7716089372
alex.holt@inmarsat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release

The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye